Drug Trial Radar · NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Feb 15, 2022
Primary completion
Nov 16, 2022
Study completion Nov 16, 2022
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jan 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
Conditions
- CLL/SLL
- NHL
- MCL
- MZL
- Lymphoplasmacytic Lymphoma
- Waldenstrom Macroglobulinemia
- Follicular Lymphoma
- DLBCL
- Richter Syndrome
Interventions
HMPL-760Drug
Administered orally QD for 28-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTsTime frame: Up to 28 days after first dose of study drug
- Incidence of AEs/SAEsTime frame: From 1st dose to within 30 days of last dose
- MTDTime frame: From 1st dose to within 30 days of last dose
- RP2DTime frame: From 1st dose to within 30 days of last dose
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
Innovative Clinical Research
Anaheim, California
Emory University Hospital
Atlanta, Georgia
Tulane Cancer Center
New Orleans, Louisiana
Johns Hopkins Clinical Research Center
Baltimore, Maryland
AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company
Kansas City, Missouri
Center For Advanced Medicine
St Louis, Missouri
Summit Medical Group
Florham Park, New Jersey
New York University Langone Med Center. Lab
New York, New York
Clinical Research Alliance
Westbury, New York
Renovatio Clinical
El Paso, Texas
Oncology Consultants, P.A.
Houston, Texas
Renovatio Clinical
The Woodlands, Texas
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Centre Antoine Lacassagne
Nice, Alpes Maritimes, France
Hôpital Saint-Antoine
Paris, Paris, France
Groupe Hospitalier Pitie-Salpetriere
Paris, Paris, France
Institut Gustave Roussy
Villejuif, Val De Marne, France
CHU Poitiers - Hôpital la Milétrie
Poitiers, Vienne, France
Hadassah University Hospital - Ein Kerem
Jerusalem, Israel
Rabin Medical Center-Beilinson Campus
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lazio, Roma, Italy
Fondazione del Piemonte per l'Oncologia IRCC Candiolo
Candiolo, Torino, Italy
Pratia Onkologia Katowice
Katowice, Poland
Wojewodzki Szpital Specjalistyczny w Legnicy
Legnica, Poland
Centrum Medyczne Pratia Poznan
Skórzewo, Poland
MICS Centrum Medyczne Torun
Torun, Poland
Hospital del Mar
Barcelona, Spain
MD Anderson Cancer Centre
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.